Verition Fund Management’s Starling Oncology STLN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-18,020
Closed -$62.9K 3951
2025
Q3
$62.9K Sell
18,020
-121,743
-87% -$417K ﹤0.01% 3640
2025
Q2
$287K Buy
+139,763
New +$349K ﹤0.01% 3225

Other funds holding STLN

Verition Fund Management's STLN Position: Q4 2025 in Review

Verition Fund Management sold out of Starling Oncology (STLN) in Q4 2025, closing a stake of 18,020 shares — an estimated $62.9K sold.

Verition Fund Management first reported a position in STLN in Q2 2025 and held it in 2 quarters. The position peaked at $287K in Q2 2025. 117 funds tracked by Wall St. Rank hold STLN as of Q4 2025.

  • Verition Fund Management reported no remaining Starling Oncology position as of Q4 2025 after selling out during the quarter.
  • Verition Fund Management sold 18,020 Starling Oncology shares in Q4 2025, an estimated $62.9K.
  • Verition Fund Management first reported a position in Starling Oncology in Q2 2025 and held it in 2 quarters.
  • Verition Fund Management's Starling Oncology position peaked at $287K in Q2 2025.
  • 117 funds tracked by Wall St. Rank held Starling Oncology as of Q4 2025.

Based on Verition Fund Management's 13F filing for Q4 2025, filed 13 Feb 2026.